SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that John J. Carbone, MD has been appointed to the Board of Directors. Dr. Carbone fills the vacancy left by the resignation of Murray Gross on February 13, 2009.
Michael L. Krall, President/CEO and Chairman of PURE Bioscience, commented, "We believe that SDC has tremendous potential in numerous healthcare applications, and we are extremely pleased and honored to have someone with Dr. Carbone's experience and leadership on our Board. Dr. Carbone's guidance will be a great benefit to PURE in our efforts to fully develop a market for SDC in healthcare."
Dr. Carbone stated, "I have always been fascinated with new technologies in my field, and I think that the SDC molecule presents intriguing and promising opportunities in medicine. I'm looking forward to supporting the research for and commercialization of SDC in medicine."
Dr. Carbone is a Board Certified Orthopedic Surgeon and a Fellow of the American Academy of Orthopedic Surgeons. Since 2004 he has served as the Director, Orthopedic Spine Services at Harbor Hospital in Baltimore, MD.
Dr. Carbone specializes in the design and use of orthopedic implants and surgical instruments as well as the biomechanics and clinical outcomes of spinal surgery. Currently, he holds several patents for orthopedic prosthetic devices and implants and is a consulting surgeon to the National Aquarium in Baltimore, MD. Dr. Carbone specializes in the treatment of all types of spinal pathology from degenerative cervical and lumbar disease to reconstructive deformity, failed spine surgery syndrome, and minimally invasive spinal surgery.
Dr. Carbone received a bachelor's degree in engineering from The
Dr. Carbone's combination of medical and engineering talents has led to a distinguished career in orthopedics research and design. His primary research focuses on the biomechanical design and use of orthopedic implants in spinal fusion.
Dr. Carbone serves on the PURE Bioscience Board as an independent director and a member of the audit committee. Dr. Carbone is not, and has not been for the past three years, employed by the Company or by any parent or subsidiary of the Company and has not accepted any payments from the Company or any parent or subsidiary of the Company during the current or any of the past three fiscal years. No family relationships exist between Dr. Carbone and PURE Bioscience, its directors or officers.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Investor Contact: PURE Media Contact: Paul G. Henning, Vice President Michael Gallo Cameron Associates Gutenberg Communications (212) 554-5462 (212) 239-8594 firstname.lastname@example.org email@example.com
|SOURCE PURE Bioscience|
Copyright©2009 PR Newswire.
All rights reserved